Two-Drug combo may boost outcomes for High-Risk PAH patients

This study compares starting with two oral medications (tadalafil and ambrisentan) versus one medication alone in people newly diagnosed with pulmonary arterial hypertension (PAH) who also have at least two heart-related conditions. The goal is to see if the two-drug approach leads to better risk scores after 24 weeks. About 186 participants will be enrolled, and the results aim to guide treatment for this often-excluded high-risk group.